|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
New Jersey Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New JerseyLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Caladrius Biosciences, Inc.
| | | Phone: | (212) 584-4180 | Year Established: | 2002 | Ticker: | CLBS | Exchange: | NASDAQ | Main Contact: | Martin E. Schmieg, VP, Corporate Development | | Other Contacts: | Joseph Talamo, Senior VP & CFO Robert A. Preti, PhD, Senior VP, Development and Technical Operations & CTO David J. Mazzo, Phd, CEO Douglas W. Losordo, MD, FACC, FAHA, Senior VP, Clinical, Medical and Regulatory Affairs & CMO Todd Girolamo, General Counsel
| | Company Description | Caladrius Biosciences, formerly Neostem, the Corniche Group and Phase III Medical, is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. In addition, the Company seeks to advance additional proprietary platform technologies through grants or out-licensing. | |
|
|
|
|
|